- Based on the recommendation from the independent Data Monitoring Committee, Regeneron Pharmaceuticals (REGN -0.6%) will suspend enrollment of participants requiring high-flow oxygen or mechanical ventilation in its ongoing study of its COVID-19 antibody cocktail, REGN-COV2, in hospitalized patients. The action was prompted by a potential safety signal and an unfavorable benefit/risk profile.
- Enrollment of hospitalized patients requiring no or low-flow oxygen will continue.
- The outpatient trial will continue without modification.
- REGN-COV2 consists of two monoclonal antibodies - REGN10933 and REGN10987 - designed to block the infectivity of SARS-CoV-2.
https://seekingalpha.com/news/3629118-regeneron-to-exclude-severely-critically-ill-covidminus-19-patients-from-antibody-cocktail
Friday, October 30, 2020
Regeneron to exclude severely/critically ill COVID-19 patients from antibody cocktail study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.